2012-09-13 18:14:20 -

Pluristem Therapeutics (NASDAQ:PSTI) gapped down 15% Thursday morning after an
announcement that the company will be raising capital through the sale of $32M
in common stock and warrants. The company will sell 8M units - each unit
consisting of one share of common stock and a warrant to purchase 0.35 shares of
the stock- at $4 a piece. Shares are, however, already rebounding slightly in
the late morning as investors are still interested in Pluristem's proprietary
placental cell-based therapies. Shares of the company have more than doubled in
the last six months, and closed Wednesday, before the financing announcement, at
$4.54. PSTI's visibility improved drastically in July - average volume more than
quadrupled - after a series of bullish articles were published on Seeking Alpha.

On August 30th, Pluristem filed   for Orphan Drug Status in treating aplastic
anemia with its PLacental eXpanded (PLX) cells, setting the stage for a catalyst
if the treatment receives approval in the next few months. The company also
commenced with a phase II trial of PLX cells to treat intermittent claudication
in August. PSTI should remain weak through the day, however the question is
whether or not increased visibility and volume in the last two months will
continue after Thursday's losses. If so, bullish sentiment will help buoy shares
relatively quickly. Otherwise, it may not be until PSTI receives orphan drug
approval that shares strengthen significantly.

Click here to see this article at PropThink.com

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at  www.propthink.com.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: PropThink via Thomson Reuters ONE
[HUG#1640952]